Nuvectra to Report Second Quarter 2019 Financial Results on July 31, 2019
July 17 2019 - 8:30AM
Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical
device company, announced today that it will release its financial
results for the second quarter ended June 30, 2019 on Wednesday,
July 31, 2019 after market close.
Nuvectra will hold a conference call on
Wednesday, July 31, 2019 at 4:30pm ET to discuss the results. The
dial in numbers are (844) 882-7830 for domestic callers and (574)
990-9704 for international callers. The conference ID is
3264026. A live webcast of the conference call will be
available on the investor relations section of the Company’s
website at http://investors.nuvectramed.com/.
A replay of the call will be available starting
on July 31, 2019 through August 7, 2019. To access the replay, dial
(855) 859-2056 for domestic callers and (404) 537-3406 for
international callers and enter access code 3264026. The webcast
will be available in the investor relations section of the
Company’s website for 90 days following the completion of the
call.
About Nuvectra Corporation
Nuvectra® is a neurostimulation company committed to helping
physicians improve the lives of people with chronic conditions. The
Algovita® Spinal Cord Stimulation (SCS) System is our first
commercial offering and is CE marked and FDA approved for the
treatment of chronic intractable pain of the trunk and/or limbs.
Our innovative technology platform also has capabilities under
development to support other indications such as sacral
neuromodulation (SNM) for the treatment of overactive bladder, and
deep brain stimulation (DBS) for the treatment of Parkinson’s
Disease. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts:
Nuvectra Corporation
Jennifer Kosharek
(214) 474-3107
jkosharek@nuvectramed.com |
Investor Contact:The Ruth
GroupTram Bui(646) 536-7035
investors@nuvectramed.com |
Nuvectra (NASDAQ:NVTR)
Historical Stock Chart
From Oct 2024 to Nov 2024
Nuvectra (NASDAQ:NVTR)
Historical Stock Chart
From Nov 2023 to Nov 2024